BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26344002)

  • 21. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
    Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell growth of BG-1 ovarian cancer cells is promoted by di-n-butyl phthalate and hexabromocyclododecane via upregulation of the cyclin D and cyclin-dependent kinase-4 genes.
    Park MA; Hwang KA; Lee HR; Yi BR; Jeung EB; Choi KC
    Mol Med Rep; 2012 Mar; 5(3):761-6. PubMed ID: 22179484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced growth of BG-1 ovarian cancer cells by 17β-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression.
    Kang NH; Hwang KA; Kim TH; Hyun SH; Jeung EB; Choi KC
    Mol Med Rep; 2012 Jul; 6(1):151-6. PubMed ID: 22552626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of BG-1 Ovarian Cancer Cells Expressing Estrogen Receptors with Lambda-cyhalothrin and Cypermethrin Caused a Partial Estrogenicity Via an Estrogen Receptor-dependent Pathway.
    Kim CW; Go RE; Choi KC
    Toxicol Res; 2015 Dec; 31(4):331-7. PubMed ID: 26877835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E.
    Kashima H; Shiozawa T; Miyamoto T; Suzuki A; Uchikawa J; Kurai M; Konishi I
    Endocr Relat Cancer; 2009 Mar; 16(1):113-22. PubMed ID: 18852162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
    Chen J; Zeng J; Xin M; Huang W; Chen X
    Horm Metab Res; 2011 Sep; 43(10):681-6. PubMed ID: 21932171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoflavones inhibit proliferation of ovarian cancer cells in vitro via an estrogen receptor-dependent pathway.
    Chen X; Anderson JJ
    Nutr Cancer; 2001; 41(1-2):165-71. PubMed ID: 12094620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
    Hall JM; Korach KS
    Mol Endocrinol; 2003 May; 17(5):792-803. PubMed ID: 12586845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
    Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
    Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 4-nonylphenol and bisphenol A on stimulation of cell growth via disruption of the transforming growth factor-β signaling pathway in ovarian cancer models.
    Park MA; Choi KC
    Chem Res Toxicol; 2014 Jan; 27(1):119-28. PubMed ID: 24308608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WAP four-disulfide core domain protein 2 mediates the proliferation of human ovarian cancer cells through the regulation of growth- and apoptosis-associated genes.
    Chen Y; Mu X; Wang S; Zhao L; Wu Y; Li J; Li M
    Oncol Rep; 2013 Jan; 29(1):288-96. PubMed ID: 23129262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influence of estrogen and progestin on nm23-H1 expression in epithelial ovarian cancer cell lines via activation of phosphorylation signaling].
    Hua KQ; Yao LQ; Cao Q; Huang Y; Zhao YQ; Feng YJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):756-61. PubMed ID: 17327034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benzophenone-1 and nonylphenol stimulated MCF-7 breast cancer growth by regulating cell cycle and metastasis-related genes via an estrogen receptor α-dependent pathway.
    In SJ; Kim SH; Go RE; Hwang KA; Choi KC
    J Toxicol Environ Health A; 2015; 78(8):492-505. PubMed ID: 25849766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with kaempferol suppresses breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models.
    Kim SH; Hwang KA; Choi KC
    J Nutr Biochem; 2016 Feb; 28():70-82. PubMed ID: 26878784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
    Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
    Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
    Doisneau-Sixou SF; Cestac P; Chouini S; Carroll JS; Hamilton AD; Sebti SM; Poirot M; Balaguer P; Faye JC; Sutherland RL; Favre G
    Endocrinology; 2003 Mar; 144(3):989-98. PubMed ID: 12586776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells.
    Kang SK; Choi KC; Tai CJ; Auersperg N; Leung PC
    Endocrinology; 2001 Feb; 142(2):580-8. PubMed ID: 11159828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cyclin D1 regulates lung cancer invasion and metastasis].
    Li ZL; Shao SH; Jiao F; Yue Z; Ma Y
    Sheng Li Xue Bao; 2012 Feb; 64(1):55-61. PubMed ID: 22348961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
    Liu H; Shi H; Fan Q; Sun X
    Tumour Biol; 2016 Aug; 37(8):10161-75. PubMed ID: 26831658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
    Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
    Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.